Literature DB >> 9580247

Effects of a short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus.

A Caixàs1, A Pérez, A Payés, C Otal, G Carreras, J Ordóñez-Llanos, J Reviriego, J H Anderson, A de Leiva.   

Abstract

Insulin Lispro (IL) is a short-acting insulin analog that better reproduces the physiological postprandial insulin profile. The aim of this study was to compare the effects of intensive insulin therapy on lipid metabolism using preprandial IL and regular insulin (RI) in 10 insulin-dependent diabetes mellitus (IDDM) subjects. The mean hemoglobin A1c (HbA1c) at baseline was 7.13% +/- 1.2% and did not change after both treatments. In IDDM patients, total cholesterol and triglyceride levels appeared lower after RI than after IL. The low-density lipoprotein (LDL) to high-density lipoprotein (HDL) ratio significantly decreased only after RI (baseline, 2.01 +/- 0.6; IL, 1.88 +/- 0.6; RI, 1.71 +/- 0.5, P < .05). Although no very-low-density lipoprotein (VLDL) composition abnormalities were observed at baseline, the protein content was lower (P < .05) after IL (8.13% +/- 2.93%) than after RI (11.93% +/- 3.41%). Intermediate-density lipoprotein (IDL) protein depletion at baseline (6.14% +/- 6.84%) was normalized after both treatments (IL, 11.09% +/- 12.14%; RI, 10.38% +/- 16.68%, P < .05). LDL, HDL, HDL2, and HDL3 composition abnormalities were similar after both treatments and did not normalize. IDDM and control subjects showed similar LDL subfraction distribution at baseline and after both treatments. Two-hour postprandial VLDL composition alterations, although improved after RI, completely normalized after IL (P < .05). Lipoprotein lipase (LPL) and cholesteryl ester transfer protein (CETP) activities were similar to the control group and did not change after both treatments. Hepatic lipase (HL) activity was lower in diabetic patients (39.6 +/- 35.2 v 87.0 +/- 27.1 U/L, P < .01) and remained lower after both treatments. In conclusion, in IDDM patients, IL (injected immediately before the meal) may offer small different effects on lipoprotein metabolism versus RI (injected 30 minutes before the meal) that, taken together, do not seem relevant.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580247     DOI: 10.1016/s0026-0495(98)90045-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

Review 1.  Insulin analogues and management of diabetes mellitus.

Authors:  B Vaidyanathan; P S Menon
Journal:  Indian J Pediatr       Date:  2000-06       Impact factor: 1.967

2.  Role of SN1 lipases on plasma lipids in metabolic syndrome and obesity.

Authors:  Verónica Miksztowicz; Laura Schreier; Mary McCoy; Diego Lucero; Eduardo Fassio; Jeffrey Billheimer; Daniel J Rader; Gabriela Berg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-23       Impact factor: 8.311

3.  Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-03-01

Review 4.  Cardiovascular risk in double diabetes mellitus--when two worlds collide.

Authors:  Stephen J Cleland
Journal:  Nat Rev Endocrinol       Date:  2012-04-10       Impact factor: 43.330

5.  Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men.

Authors:  L Duvillard; E Florentin; M L Lalanne-Mistrich; J M Petit; S Baillot-Rudoni; A Brun-Pacaud; J M Brun; P Gambert; B Vergès
Journal:  Diabetologia       Date:  2005-05-26       Impact factor: 10.122

Review 6.  Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

Authors:  S J Cleland; B M Fisher; H M Colhoun; N Sattar; J R Petrie
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

Review 7.  Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.

Authors:  Birgit Fullerton; Andrea Siebenhofer; Klaus Jeitler; Karl Horvath; Thomas Semlitsch; Andrea Berghold; Johannes Plank; Thomas R Pieber; Ferdinand M Gerlach
Journal:  Cochrane Database Syst Rev       Date:  2016-06-30

8.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Authors:  Sumeet R Singh; Fida Ahmad; Avtar Lal; Changhua Yu; Zemin Bai; Heather Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

9.  Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.

Authors:  Birgit Fullerton; Andrea Siebenhofer; Klaus Jeitler; Karl Horvath; Thomas Semlitsch; Andrea Berghold; Ferdinand M Gerlach
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

Review 10.  An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.

Authors:  C Pratoomsoot; H T Smith; A Kalsekar; K S Boye; J Arellano; W J Valentine
Journal:  Diabet Med       Date:  2009-08       Impact factor: 4.359

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.